4.8 Article

An injectable bone marrow-like scaffold enhances T cell immunity after hematopoietic stem cell transplantation

Journal

NATURE BIOTECHNOLOGY
Volume 37, Issue 3, Pages 293-+

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41587-019-0017-2

Keywords

-

Funding

  1. National Institutes of Health [UL1 TR002541, U19 HL129903, R01 EB023287]
  2. Cancer Research Institute Postdoctoral Fellowship
  3. Blavatnik Biomedical Accelerator Program at Harvard University

Ask authors/readers for more resources

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for multiple disorders, but deficiency and dysregulation of T cells limit its utility. Here we report a biomaterial-based scaffold that mimics features of T cell lymphopoiesis in the bone marrow. The bone marrow cryogel (BMC) releases bone morphogenetic protein-2 to recruit stromal cells and presents the Notch ligand Delta-like ligand-4 to facilitate T cell lineage specification of mouse and human hematopoietic progenitor cells. BMCs subcutaneously injected in mice at the time of HSCT enhanced T cell progenitor seeding of the thymus, T cell neogenesis and diversification of the T cell receptor repertoire. Peripheral T cell reconstitution increased similar to 6-fold in mouse HSCT and similar to 2-fold in human xenogeneic HSCT. Furthermore, BMCs promoted donor CD4(+) regulatory T cell generation and improved survival after allogeneic HSCT. In comparison to adoptive transfer of T cell progenitors, BMCs increased donor chimerism, T cell generation and antigen-specific T cell responses to vaccination. BMCs may provide an off-the-shelf approach for enhancing T cell regeneration and mitigating graft-versus-host disease in HSCT.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available